These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 17579631

  • 1. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
    Berthiaume M, Laplante M, Tchernof A, Deshaies Y.
    Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
    [Abstract] [Full Text] [Related]

  • 2. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids.
    Berthiaume M, Sell H, Lalonde J, Gélinas Y, Tchernof A, Richard D, Deshaies Y.
    Am J Physiol Regul Integr Comp Physiol; 2004 Nov; 287(5):R1116-23. PubMed ID: 15256367
    [Abstract] [Full Text] [Related]

  • 3. Early induction of a brown-like phenotype by rosiglitazone in the epicardial adipose tissue of fatty Zucker rats.
    Distel E, Penot G, Cadoudal T, Balguy I, Durant S, Benelli C.
    Biochimie; 2012 Aug; 94(8):1660-7. PubMed ID: 22575275
    [Abstract] [Full Text] [Related]

  • 4. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
    Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y.
    Int J Obes (Lond); 2009 May; 33(5):601-4. PubMed ID: 19223847
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptor γ activation favours selective subcutaneous lipid deposition by coordinately regulating lipoprotein lipase modulators, fatty acid transporters and lipogenic enzymes.
    Blanchard PG, Turcotte V, Côté M, Gélinas Y, Nilsson S, Olivecrona G, Deshaies Y, Festuccia WT.
    Acta Physiol (Oxf); 2016 Jul; 217(3):227-39. PubMed ID: 26918671
    [Abstract] [Full Text] [Related]

  • 6. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
    Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE.
    J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
    [Abstract] [Full Text] [Related]

  • 7. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice.
    Lee MS, Kim CT, Kim Y.
    Ann Nutr Metab; 2009 Jan; 54(2):151-7. PubMed ID: 19390166
    [Abstract] [Full Text] [Related]

  • 8. Regional differences in the expression of genes involved in lipid metabolism in adipose tissue in response to short- and medium-term fasting and refeeding.
    Palou M, Sánchez J, Priego T, Rodríguez AM, Picó C, Palou A.
    J Nutr Biochem; 2010 Jan; 21(1):23-33. PubMed ID: 19157823
    [Abstract] [Full Text] [Related]

  • 9. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
    Walker GE, Marzullo P, Verti B, Guzzaloni G, Maestrini S, Zurleni F, Liuzzi A, Di Blasio AM.
    Obesity (Silver Spring); 2008 Sep; 16(9):1983-91. PubMed ID: 19186324
    [Abstract] [Full Text] [Related]

  • 10. Involvement of adipose tissues in the early hypolipidemic action of PPARgamma agonism in the rat.
    Laplante M, Festuccia WT, Soucy G, Gélinas Y, Lalonde J, Deshaies Y.
    Am J Physiol Regul Integr Comp Physiol; 2007 Apr; 292(4):R1408-17. PubMed ID: 17170230
    [Abstract] [Full Text] [Related]

  • 11. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue.
    Joosen AM, Bakker AH, Kersten S, Westerterp KR.
    Br J Nutr; 2008 Mar; 99(3):487-93. PubMed ID: 18177513
    [Abstract] [Full Text] [Related]

  • 12. Energy restriction enhances therapeutic efficacy of the PPARgamma agonist, rosiglitazone, through regulation of visceral fat gene expression.
    Moore GB, Pickavance LC, Briscoe CP, Clapham JC, Buckingham RE, Wilding JP.
    Diabetes Obes Metab; 2008 Mar; 10(3):251-63. PubMed ID: 18269641
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism.
    Laplante M, Festuccia WT, Soucy G, Gélinas Y, Lalonde J, Berger JP, Deshaies Y.
    Diabetes; 2006 Oct; 55(10):2771-8. PubMed ID: 17003342
    [Abstract] [Full Text] [Related]

  • 14. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
    Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Mutoh S.
    Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
    [Abstract] [Full Text] [Related]

  • 15. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
    Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB, Hawley JA.
    Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
    [Abstract] [Full Text] [Related]

  • 16. Increased de novo lipogenesis in liver contributes to the augmented fat deposition in dexamethasone exposed broiler chickens (Gallus gallus domesticus).
    Cai Y, Song Z, Zhang X, Wang X, Jiao H, Lin H.
    Comp Biochem Physiol C Toxicol Pharmacol; 2009 Aug; 150(2):164-9. PubMed ID: 19393339
    [Abstract] [Full Text] [Related]

  • 17. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
    Törüner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, Aktürk M, Karakoç A, Ayvaz G, Arslan M.
    Horm Metab Res; 2004 Apr; 36(4):226-30. PubMed ID: 15114521
    [Abstract] [Full Text] [Related]

  • 18. PPARgamma agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control.
    Festuccia WT, Laplante M, Berthiaume M, Gélinas Y, Deshaies Y.
    Diabetologia; 2006 Oct; 49(10):2427-36. PubMed ID: 16906479
    [Abstract] [Full Text] [Related]

  • 19. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
    Ljungberg A, Lindén D, Améen C, Bergström G, Oscarsson J.
    Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
    [Abstract] [Full Text] [Related]

  • 20. Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.
    Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R.
    Eur J Pharmacol; 2004 May 03; 491(2-3):195-206. PubMed ID: 15140637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.